genprowebdirectory
News
Insights
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
News
Novartis
AveXis Turns to Catalent’s Paragon for Additional Gene Therapy Manufacturing Capacity
News
Anticancer Immune Cells Identified Using Antigen Receptor Barcode Tracker
News
Firm Up that Skin with Loose RNA
News
Anorexia Partly a Metabolic Disorder, Suggests Genomic Study
News
27-Year-Old Suspect Charged in Murder of Max Planck Institute Scientist
Insights
Insights
Top 10 Biopharma IPOs of January–June 2019
Tech Exclusives
A Toolbox for Keeping CRISPR in Check
Tech Exclusives
Drones Land in the Cell and Gene Therapy Space
Tech Exclusives
An Integrated Digital Vision for Biomanufacturing’s Future
Tech Exclusives
CRISPR and LASER ART Eliminate HIV from Mice
A-Lists
Insights
Top 10 Biopharma IPOs of January–June 2019
Insights
Top 10 M&A Deals of January–June 2019
Insights
The Top 10 Highest-Paid Women Executives in Biopharma
Insights
Top 50 NIH-Funded Institutions of 2019
July 2019 Vol. 39 No. 7
25 Up-and-Coming Gene Therapies of 2019
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Novartis
AveXis Turns to Catalent’s Paragon for Additional Gene Therapy Manufacturing Capacity
News
Anticancer Immune Cells Identified Using Antigen Receptor Barcode Tracker
News
Firm Up that Skin with Loose RNA
News
Anorexia Partly a Metabolic Disorder, Suggests Genomic Study
Magazine
July 2019 Vol. 39 No. 7
CRISPR-Accelerated Gene Drives Pump the Brakes
July 2019 Vol. 39 No. 7
CRISPR Cinema: Scenes from the Cutting Edge
Tech Exclusives
Immunotherapy Targets Emerging Infectious Diseases
July 2019 Vol. 39 No. 7
Single-Cell Sequencing Sifts through Multiple Omics
Tech Exclusives
Bioreactor Design Adapts to Biopharma’s Changing Needs
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
GENcast
GENcast: A Biological GPS That Guides Awareness through Cellular Space
July 2019 Vol. 39 No. 7
Full-Length Transcript Sequencing—No Assembly Required
July 2019 Vol. 39 No. 7
Plasma Proteomics with NanoLC-MS
July 2019 Vol. 39 No. 7
Advanced Mass Spectrometry Drives Translational Cancer Biomarker Research beyond Discovery
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Home
Companies
Merck & Co
Merck & Co
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Merck & Co
Merck & Co., Skyhawk Collaborate on RNA-Binding Small Molecule Therapies
Merck & Co
Merck & Co. Expands Pipeline in Cancer, Fibrosis, Autoimmune Diseases by Acquiring Tilos for Up to $773M
Merck & Co
Merck & Co. to Acquire Peloton for Up to $2.2B, Adding Late-Stage Kidney Cancer Candidate
Merck & Co
Citing “Strong Sales,” Pension Manager Buys Partial Keytruda Rights for $1.3B
Merck & Co
Merck & Co. Plans Jobs Cuts, Shutdowns in Up-to-$1.2B Manufacturing Restructuring
Merck & Co
Merck, King’s Launch $344M+ Chronic Pain Drug Collaboration
Merck & Co
Merck to Acquire Immune Design for $300M, Boosting Immunotherapy Vaccine Pipeline
Merck & Co
Merck & Co. Partners with Sutro on Cytokine Derivatives for Cancer,...
Merck & Co
Merck Invests $125M in Moderna in Expanded mRNA Cancer Vaccine Partnership
Merck & Co
Incyte, Merck & Co. Halt Phase III Trial After Epacadostat/Keytruda Combination...
Merck & Co
Merck & Co., Eisai Launch Up-to-$5.76B Cancer Partnership
Merck & Co
Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M
Merck & Co
Moderna Raises $500M Financing for mRNA R&D, Manufacturing
Merck & Co
Menlo Therapeutics Files for Up-to-$97.75M IPO
Merck & Co
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise
Load more
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
